<DOC>
	<DOCNO>NCT03007446</DOCNO>
	<brief_summary>This Prospective，Single-center，Single-arm，Open-label exploratory clinical trial evaluate efficacy safety Convension Surgery Apatinib plus SOX patient unresectable gastric cancer .</brief_summary>
	<brief_title>The Study Conversion Surgery Apatinib Combination With SOX Patients With Unresectable Gastric Cancer</brief_title>
	<detailed_description>Gastric cancer second common cause cancer‑related death worldwide , surgical resection early stage improve treatment outcomes.However , many patient diagnose unresectable advanced metastatic stage disease lose radical surgery opportunity . Systemic chemotherapy lead treatment prolongs survival time patient . Approximate 20 patient unresectable gastric cancer enrol study , investigator evaluate efficacy security Apatinib + SOX ( oxaliplatin+S-1 ) unresectable gastric cancer .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Histologically prove gastric adenocarcinoma ; 2 . At least unresectable factor operation via CT , MRI , PETCT : difficult resection locally advance gastric cancer ( T4b ) ; hepatic metastasis ( H1 ; five lesion , total diameter ≤8 cm ) ; Peritoneal metastasis ( CY1 , P1 ) ; 3 . Definitely diagnose unresectable gastric cancer via exploratory laparoscopy laparotomy ; 4 . ECOG performance status 02 ; 5 . Age 1870 year old , Life expectancy estimate 3 month ; 6 . For result blood routine test biochemical test : 1 . Hgb ≥ 80g/L , 2 . WBC ≥ 4000/mm3 , 3 . ANC ≥ 1.5×109/L , 4. platelet ≥ 80×109/L 5 . ALT AST ≤ 2.5 x upper normal limit ( UNL ) , ≤ 5 x UNL（Hematogenous metastases） , 6 . Serum Total bilirubin ≤ 1.5 X UNL , 7 . Serum Creatine ≤ 1.5 x UNL ； 7 . Good cardiac function recruitment , seizure myocardial infarction past half year , controllable hypertension coronary heart disease ; 8 . Not concomitant uncontrollable benign disease recruitment ( e.g . infection kidney , lung liver ) ; 9. informed consent . 1 . Subjects poorcontrolled arterial hypertension ( systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mm Hg ) despite standard medical management ; Coronary heart disease great Class I ; Ilevel arrhythmia ( include QT interval prolongation , man ≥ 450 m , woman ≥ 470 m ) together Class I cardiac dysfunction ; Patients positive urinary protein ; 2 . Factors could effect oral medication ( inability swallow , chronic diarrhea intestinal obstruction ) ; 3 . Subjects high gastrointestinal bleeding risk , include follow condition : local active ulcer lesion positive fecal occult blood test ( ++ ) ; history black stool , vomit blood past 2 month ; 4 . Contraindications include allergy apatinib and/or accessory , active bleeding , intestinal perforation , intestinal obstruction , within 30 day surgery , drug poorcontrolled hypertension , Class ⅢⅣ cardiac dysfunction （NYHA standard） , severe hepatic renal dysfunction（level 4）if apatinib use consider ; 5 . Abnormal Coagulation ( INR &gt; 1.5 , APTT &gt; 1.5 UNL ) , tendency bleed ; 6 . Pregnant lactating woman ; 7 . Any condition might place patient undue risk preclude patient completing study ; 8 . Treatment prior radiotherapy , chemotherapy , Targeted therapy immunotherapy ; 9 . Other condition regiment investigator ' discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Apatinib</keyword>
	<keyword>SOX</keyword>
	<keyword>Conversion Surgery</keyword>
	<keyword>unresectable gastric cancer</keyword>
</DOC>